Description
Anti-VEGF-A Antibody, Non-Fucosylated (BioBet-031ZP) is a human monoclonal IgG1 antibody against VEGF-A. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Colorectal cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced VEGF-A antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
vascular endothelial growth factor A
Alternative Names
VEGFA;vascular endothelial growth factor A;vascular endothelial growth factor , VEGF;VEGF A;VPF;vascular permeability factor;VEGF;
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with VEGFA include Microvascular Complications Of Diabetes 1 and Poems Syndrome.
Related Pathways
Its related pathways are HIF1Alpha Pathway and Cell adhesion_Plasmin signaling.
Function
The activity of growth factors in angiogenesis, angiogenesis and endothelial cell growth. Induce endothelial cell proliferation, promote cell migration, inhibit cell apoptosis, and induce vascular permeability. It binds to FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparin sulfate and heparin. NRP1/Neuropilin-1 binds to subtypes of VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR, but does not activate downstream signaling pathways, does not activate angiogenesis, and inhibit tumor growth. Binding to the NRP1 receptor initiates the signaling pathways required for motor neuron axon guidance and cell body migration, including the migration of facial motor neurons from rhombomere 4 to rhombomere 6 tails during embryonic development (similar).
Post-translational modifications
1. Glycosylation at Asn101 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-031ZP
Description
Bevacizumab is an angiogenesis inhibitor and monoclonal antibody. The drug was approved for medical use in the United States in 2004 for the treatment of a variety of cancers, including colon cancer, lung cancer, glioblastoma, and renal cell carcinoma. Bevacizumab slows the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A).
Antibody Indication
Glioblastomas
Metastatic Breast Cancer
Metastatic Colorectal Cancer (MCRC)
Metastatic Renal Cell Carcinoma
Recurrent Cervical Cancer
Nonsquamous cell Non-small cell lung cancer
Recurrent platinum drug resistant Fallopian tube cancer
Recurrent platinum drug resistant Ovarian cancer
Recurrent platinum drug resistant primary peritoneal cancer
Recurrent, IV-B Cervical cancer
Refractory Cervical cancer
